Market closed

Ventyx Biosciences/$VTYX

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Ventyx Biosciences

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Ticker

$VTYX
Sector
Health Care
Trading on
NASDAQ

Industry

Pharmaceuticals
Headquarters
San Diego, United States

Employees

75
Website
ventyxbio.com

VTYX Metrics

BasicAdvanced
$138M
-
-$2.33
0.37
-

$138M

0.37

$11.48

$1.67

1.9M

23.523

22.371

3.596

3.959

-33.39%

-54.24%

0.49

0.49

-0.8

-25.65%

-56.08%

What the Analysts think about VTYX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Ventyx Biosciences stock.

VTYX Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

VTYX Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

VTYX News

AllArticlesVideos
Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

GlobeNewsWire·20 hours ago
VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ventyx Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ventyx Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

GlobeNewsWire·1 month ago
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VTYX

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Ventyx Biosciences stock?

Ventyx Biosciences (VTYX) has a market cap of $138M as of January 15, 2025.

What is the P/E ratio for Ventyx Biosciences stock?

The price to earnings (P/E) ratio for Ventyx Biosciences (VTYX) stock is 0 as of January 15, 2025.

Does Ventyx Biosciences stock pay dividends?

No, Ventyx Biosciences (VTYX) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Ventyx Biosciences dividend payment date?

Ventyx Biosciences (VTYX) stock does not pay dividends to its shareholders.

What is the beta indicator for Ventyx Biosciences?

Ventyx Biosciences (VTYX) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.